Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessCompaniesCipla loses PetArmor case in US appeals court

    Cipla loses PetArmor case in US appeals court

    Drugmaker Cipla said on Thursday a US appeals court had upheld a district court's ruling which last year declared a patent infringement by Cipla over animal healthcare drug PetArmor Plus.

    June 08, 2012 / 08:38 IST
       
       
      26 Aug, 2025 12:21
      Volume
      Todays L/H
      More

      Drugmaker Cipla said on Thursday a US appeals court had upheld a district court's ruling which last year declared a patent infringement by Cipla over animal healthcare drug PetArmor Plus.


      The PetArmor Plus brand is owned by Merial Ltd, a unit of French drugmaker Sanofi, and is used to treat fleas in cats and dogs.


      Sales of Cipla's product were suspended from June 30 last year after the court of Middle District of Georgia ruled the case in favour of Merial.


      The financial implications of this case are yet to be determined, Cipla said in a statement to the Bombay Stock Exchange. "The company is examining options for preferring an appeal against the aforesaid Federal Circuit order," it added.


      Valued at USD 4.47 billion, shares in Cipla fell 0.37% to Rs 308 on Thursday when the broader Mumbai market rose 1.05%.

      first published: Jun 7, 2012 07:16 pm

      Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

      Subscribe to Tech Newsletters

      • On Saturdays

        Find the best of Al News in one place, specially curated for you every weekend.

      • Daily-Weekdays

        Stay on top of the latest tech trends and biggest startup news.

      Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347